グリコピロレート注射液のグローバル市場2023年:0.2mg/ml、0.4mg/2ml、1mg/5ml、4mg/20ml

◆英語タイトル:Global Glycopyrrolate Injection Market Research Report 2023

QYResearchが発行した調査報告書(QYR23MA8776)◆商品コード:QYR23MA8776
◆発行会社(リサーチ会社):QYResearch
◆発行日:2023年3月
◆ページ数:119
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2-3営業日)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,900 ⇒換算¥429,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD4,350 ⇒換算¥643,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,800 ⇒換算¥858,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートは世界のグリコピロレート注射液市場について調査・分析し、世界のグリコピロレート注射液市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析(0.2mg/ml、0.4mg/2ml、1mg/5ml、4mg/20ml)、用途別セグメント分析(病院、クリニック、その他)、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Accord Healthcare、Advanz Pharma、American Regent、Amneal Pharmaceuticals、Apotex、BE Pharmaceuticals、BluePoint Laboratories、Caplin Steriles、Civica、Fresenius Kabi、Gland Pharma、Hikma、Khandelwal Laboratories、Meitheal、Nivagen Pharmaceuticals、NorthStar Rx、Sandoz、Solco Healthcare、SteriMax、Xiromed、AuroMedics Pharma、Par Pharmaceutical、Piramal Critical Care、Somerset Therapeutics、West-ward Pharmaceutical、Zydus Pharmaceuticals、Hengrui Pharmaceuticals、Jiabo Pharmaceutical、Easton Biopharmaceuticalsなどが含まれています。世界のグリコピロレート注射液市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX%です。COVID-19とロシア・ウクライナ戦争の影響は、グリコピロレート注射液市場規模を推定する際に考慮しました。

・グリコピロレート注射液市場の概要
- 製品の定義
- グリコピロレート注射液のタイプ別セグメント
- 世界のグリコピロレート注射液市場規模:タイプ別分析(0.2mg/ml、0.4mg/2ml、1mg/5ml、4mg/20ml)
- グリコピロレート注射液の用途別セグメント
- 世界のグリコピロレート注射液市場規模:用途別分析(病院、クリニック、その他)
- 世界のグリコピロレート注射液市場規模予測(2018年-2029年)
- グリコピロレート注射液の平均価格推移(2018年-2029年)
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- グリコピロレート注射液市場の競争状況およびトレンド

・グリコピロレート注射液の地域別市場規模
- 北米のグリコピロレート注射液市場規模(2018年-2029年)
- アメリカのグリコピロレート注射液市場規模(2018年-2029年)
- ヨーロッパのグリコピロレート注射液市場規模(2018年-2029年)
- アジア太平洋のグリコピロレート注射液市場規模(2018年-2029年)
- 中国のグリコピロレート注射液市場規模(2018年-2029年)
- 日本のグリコピロレート注射液市場規模(2018年-2029年)
- 韓国のグリコピロレート注射液市場規模(2018年-2029年)
- インドのグリコピロレート注射液市場規模(2018年-2029年)
- オーストラリアのグリコピロレート注射液市場規模(2018年-2029年)
- 中南米のグリコピロレート注射液市場規模(2018年-2029年)
- 中東・アフリカのグリコピロレート注射液市場規模(2018年-2029年)

・タイプ別セグメント:0.2mg/ml、0.4mg/2ml、1mg/5ml、4mg/20ml
- 世界のグリコピロレート注射液のタイプ別販売量(2018年-2023年)
- 世界のグリコピロレート注射液のタイプ別売上(2018年-2023年)
- 世界のグリコピロレート注射液のタイプ別価格

・用途別セグメント:病院、クリニック、その他
- 世界のグリコピロレート注射液の用途別販売量(2018年-2023年)
- 世界のグリコピロレート注射液の用途別売上(2018年-2023年)
- 世界のグリコピロレート注射液の用途別価格

・主要企業のプロファイル:企業情報、事業概要、売上、製品ポートフォリオ、動向
Accord Healthcare、Advanz Pharma、American Regent、Amneal Pharmaceuticals、Apotex、BE Pharmaceuticals、BluePoint Laboratories、Caplin Steriles、Civica、Fresenius Kabi、Gland Pharma、Hikma、Khandelwal Laboratories、Meitheal、Nivagen Pharmaceuticals、NorthStar Rx、Sandoz、Solco Healthcare、SteriMax、Xiromed、AuroMedics Pharma、Par Pharmaceutical、Piramal Critical Care、Somerset Therapeutics、West-ward Pharmaceutical、Zydus Pharmaceuticals、Hengrui Pharmaceuticals、Jiabo Pharmaceutical、Easton Biopharmaceuticals

・産業チェーンと販売チャネルの分析
- グリコピロレート注射液産業チェーン分析
- グリコピロレート注射液の主要原材料
- グリコピロレート注射液の販売チャネル
- グリコピロレート注射液のディストリビューター
- グリコピロレート注射液の主要顧客

・グリコピロレート注射液市場ダイナミクス
- グリコピロレート注射液の業界動向
- グリコピロレート注射液市場の成長ドライバ、課題、阻害要因

・調査成果および結論

・調査方法とデータソース

Highlights
The global Glycopyrrolate Injection market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Glycopyrrolate Injection is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Glycopyrrolate Injection is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Glycopyrrolate Injection include Accord Healthcare, Advanz Pharma, American Regent, Amneal Pharmaceuticals, Apotex, BE Pharmaceuticals, BluePoint Laboratories, Caplin Steriles and Civica, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Glycopyrrolate Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glycopyrrolate Injection.
The Glycopyrrolate Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Glycopyrrolate Injection market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Glycopyrrolate Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Accord Healthcare
Advanz Pharma
American Regent
Amneal Pharmaceuticals
Apotex
BE Pharmaceuticals
BluePoint Laboratories
Caplin Steriles
Civica
Fresenius Kabi
Gland Pharma
Hikma
Khandelwal Laboratories
Meitheal
Nivagen Pharmaceuticals
NorthStar Rx
Sandoz
Solco Healthcare
SteriMax
Xiromed
AuroMedics Pharma
Par Pharmaceutical
Piramal Critical Care
Somerset Therapeutics
West-ward Pharmaceutical
Zydus Pharmaceuticals
Hengrui Pharmaceuticals
Jiabo Pharmaceutical
Easton Biopharmaceuticals
Segment by Type
0.2mg/ml
0.4mg/2ml
1mg/5ml
4mg/20ml
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Glycopyrrolate Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Glycopyrrolate Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Glycopyrrolate Injection Market Overview
1.1 Product Overview and Scope of Glycopyrrolate Injection
1.2 Glycopyrrolate Injection Segment by Type
1.2.1 Global Glycopyrrolate Injection Market Value Comparison by Type (2023-2029)
1.2.2 0.2mg/ml
1.2.3 0.4mg/2ml
1.2.4 1mg/5ml
1.2.5 4mg/20ml
1.3 Glycopyrrolate Injection Segment by Application
1.3.1 Global Glycopyrrolate Injection Market Value by Application: (2023-2029)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Glycopyrrolate Injection Market Size Estimates and Forecasts
1.4.1 Global Glycopyrrolate Injection Revenue 2018-2029
1.4.2 Global Glycopyrrolate Injection Sales 2018-2029
1.4.3 Global Glycopyrrolate Injection Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Glycopyrrolate Injection Market Competition by Manufacturers
2.1 Global Glycopyrrolate Injection Sales Market Share by Manufacturers (2018-2023)
2.2 Global Glycopyrrolate Injection Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Glycopyrrolate Injection Average Price by Manufacturers (2018-2023)
2.4 Global Glycopyrrolate Injection Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Glycopyrrolate Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Glycopyrrolate Injection, Product Type & Application
2.7 Glycopyrrolate Injection Market Competitive Situation and Trends
2.7.1 Glycopyrrolate Injection Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Glycopyrrolate Injection Players Market Share by Revenue
2.7.3 Global Glycopyrrolate Injection Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Glycopyrrolate Injection Retrospective Market Scenario by Region
3.1 Global Glycopyrrolate Injection Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Glycopyrrolate Injection Global Glycopyrrolate Injection Sales by Region: 2018-2029
3.2.1 Global Glycopyrrolate Injection Sales by Region: 2018-2023
3.2.2 Global Glycopyrrolate Injection Sales by Region: 2024-2029
3.3 Global Glycopyrrolate Injection Global Glycopyrrolate Injection Revenue by Region: 2018-2029
3.3.1 Global Glycopyrrolate Injection Revenue by Region: 2018-2023
3.3.2 Global Glycopyrrolate Injection Revenue by Region: 2024-2029
3.4 North America Glycopyrrolate Injection Market Facts & Figures by Country
3.4.1 North America Glycopyrrolate Injection Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Glycopyrrolate Injection Sales by Country (2018-2029)
3.4.3 North America Glycopyrrolate Injection Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Glycopyrrolate Injection Market Facts & Figures by Country
3.5.1 Europe Glycopyrrolate Injection Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Glycopyrrolate Injection Sales by Country (2018-2029)
3.5.3 Europe Glycopyrrolate Injection Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Glycopyrrolate Injection Market Facts & Figures by Country
3.6.1 Asia Pacific Glycopyrrolate Injection Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Glycopyrrolate Injection Sales by Country (2018-2029)
3.6.3 Asia Pacific Glycopyrrolate Injection Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Glycopyrrolate Injection Market Facts & Figures by Country
3.7.1 Latin America Glycopyrrolate Injection Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Glycopyrrolate Injection Sales by Country (2018-2029)
3.7.3 Latin America Glycopyrrolate Injection Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Glycopyrrolate Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Glycopyrrolate Injection Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Glycopyrrolate Injection Sales by Country (2018-2029)
3.8.3 Middle East and Africa Glycopyrrolate Injection Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Glycopyrrolate Injection Sales by Type (2018-2029)
4.1.1 Global Glycopyrrolate Injection Sales by Type (2018-2023)
4.1.2 Global Glycopyrrolate Injection Sales by Type (2024-2029)
4.1.3 Global Glycopyrrolate Injection Sales Market Share by Type (2018-2029)
4.2 Global Glycopyrrolate Injection Revenue by Type (2018-2029)
4.2.1 Global Glycopyrrolate Injection Revenue by Type (2018-2023)
4.2.2 Global Glycopyrrolate Injection Revenue by Type (2024-2029)
4.2.3 Global Glycopyrrolate Injection Revenue Market Share by Type (2018-2029)
4.3 Global Glycopyrrolate Injection Price by Type (2018-2029)
5 Segment by Application
5.1 Global Glycopyrrolate Injection Sales by Application (2018-2029)
5.1.1 Global Glycopyrrolate Injection Sales by Application (2018-2023)
5.1.2 Global Glycopyrrolate Injection Sales by Application (2024-2029)
5.1.3 Global Glycopyrrolate Injection Sales Market Share by Application (2018-2029)
5.2 Global Glycopyrrolate Injection Revenue by Application (2018-2029)
5.2.1 Global Glycopyrrolate Injection Revenue by Application (2018-2023)
5.2.2 Global Glycopyrrolate Injection Revenue by Application (2024-2029)
5.2.3 Global Glycopyrrolate Injection Revenue Market Share by Application (2018-2029)
5.3 Global Glycopyrrolate Injection Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Accord Healthcare
6.1.1 Accord Healthcare Corporation Information
6.1.2 Accord Healthcare Description and Business Overview
6.1.3 Accord Healthcare Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Accord Healthcare Glycopyrrolate Injection Product Portfolio
6.1.5 Accord Healthcare Recent Developments/Updates
6.2 Advanz Pharma
6.2.1 Advanz Pharma Corporation Information
6.2.2 Advanz Pharma Description and Business Overview
6.2.3 Advanz Pharma Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Advanz Pharma Glycopyrrolate Injection Product Portfolio
6.2.5 Advanz Pharma Recent Developments/Updates
6.3 American Regent
6.3.1 American Regent Corporation Information
6.3.2 American Regent Description and Business Overview
6.3.3 American Regent Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.3.4 American Regent Glycopyrrolate Injection Product Portfolio
6.3.5 American Regent Recent Developments/Updates
6.4 Amneal Pharmaceuticals
6.4.1 Amneal Pharmaceuticals Corporation Information
6.4.2 Amneal Pharmaceuticals Description and Business Overview
6.4.3 Amneal Pharmaceuticals Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Amneal Pharmaceuticals Glycopyrrolate Injection Product Portfolio
6.4.5 Amneal Pharmaceuticals Recent Developments/Updates
6.5 Apotex
6.5.1 Apotex Corporation Information
6.5.2 Apotex Description and Business Overview
6.5.3 Apotex Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Apotex Glycopyrrolate Injection Product Portfolio
6.5.5 Apotex Recent Developments/Updates
6.6 BE Pharmaceuticals
6.6.1 BE Pharmaceuticals Corporation Information
6.6.2 BE Pharmaceuticals Description and Business Overview
6.6.3 BE Pharmaceuticals Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.6.4 BE Pharmaceuticals Glycopyrrolate Injection Product Portfolio
6.6.5 BE Pharmaceuticals Recent Developments/Updates
6.7 BluePoint Laboratories
6.6.1 BluePoint Laboratories Corporation Information
6.6.2 BluePoint Laboratories Description and Business Overview
6.6.3 BluePoint Laboratories Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.4.4 BluePoint Laboratories Glycopyrrolate Injection Product Portfolio
6.7.5 BluePoint Laboratories Recent Developments/Updates
6.8 Caplin Steriles
6.8.1 Caplin Steriles Corporation Information
6.8.2 Caplin Steriles Description and Business Overview
6.8.3 Caplin Steriles Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Caplin Steriles Glycopyrrolate Injection Product Portfolio
6.8.5 Caplin Steriles Recent Developments/Updates
6.9 Civica
6.9.1 Civica Corporation Information
6.9.2 Civica Description and Business Overview
6.9.3 Civica Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Civica Glycopyrrolate Injection Product Portfolio
6.9.5 Civica Recent Developments/Updates
6.10 Fresenius Kabi
6.10.1 Fresenius Kabi Corporation Information
6.10.2 Fresenius Kabi Description and Business Overview
6.10.3 Fresenius Kabi Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Fresenius Kabi Glycopyrrolate Injection Product Portfolio
6.10.5 Fresenius Kabi Recent Developments/Updates
6.11 Gland Pharma
6.11.1 Gland Pharma Corporation Information
6.11.2 Gland Pharma Glycopyrrolate Injection Description and Business Overview
6.11.3 Gland Pharma Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Gland Pharma Glycopyrrolate Injection Product Portfolio
6.11.5 Gland Pharma Recent Developments/Updates
6.12 Hikma
6.12.1 Hikma Corporation Information
6.12.2 Hikma Glycopyrrolate Injection Description and Business Overview
6.12.3 Hikma Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Hikma Glycopyrrolate Injection Product Portfolio
6.12.5 Hikma Recent Developments/Updates
6.13 Khandelwal Laboratories
6.13.1 Khandelwal Laboratories Corporation Information
6.13.2 Khandelwal Laboratories Glycopyrrolate Injection Description and Business Overview
6.13.3 Khandelwal Laboratories Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Khandelwal Laboratories Glycopyrrolate Injection Product Portfolio
6.13.5 Khandelwal Laboratories Recent Developments/Updates
6.14 Meitheal
6.14.1 Meitheal Corporation Information
6.14.2 Meitheal Glycopyrrolate Injection Description and Business Overview
6.14.3 Meitheal Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Meitheal Glycopyrrolate Injection Product Portfolio
6.14.5 Meitheal Recent Developments/Updates
6.15 Nivagen Pharmaceuticals
6.15.1 Nivagen Pharmaceuticals Corporation Information
6.15.2 Nivagen Pharmaceuticals Glycopyrrolate Injection Description and Business Overview
6.15.3 Nivagen Pharmaceuticals Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Nivagen Pharmaceuticals Glycopyrrolate Injection Product Portfolio
6.15.5 Nivagen Pharmaceuticals Recent Developments/Updates
6.16 NorthStar Rx
6.16.1 NorthStar Rx Corporation Information
6.16.2 NorthStar Rx Glycopyrrolate Injection Description and Business Overview
6.16.3 NorthStar Rx Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.16.4 NorthStar Rx Glycopyrrolate Injection Product Portfolio
6.16.5 NorthStar Rx Recent Developments/Updates
6.17 Sandoz
6.17.1 Sandoz Corporation Information
6.17.2 Sandoz Glycopyrrolate Injection Description and Business Overview
6.17.3 Sandoz Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Sandoz Glycopyrrolate Injection Product Portfolio
6.17.5 Sandoz Recent Developments/Updates
6.18 Solco Healthcare
6.18.1 Solco Healthcare Corporation Information
6.18.2 Solco Healthcare Glycopyrrolate Injection Description and Business Overview
6.18.3 Solco Healthcare Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Solco Healthcare Glycopyrrolate Injection Product Portfolio
6.18.5 Solco Healthcare Recent Developments/Updates
6.19 SteriMax
6.19.1 SteriMax Corporation Information
6.19.2 SteriMax Glycopyrrolate Injection Description and Business Overview
6.19.3 SteriMax Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.19.4 SteriMax Glycopyrrolate Injection Product Portfolio
6.19.5 SteriMax Recent Developments/Updates
6.20 Xiromed
6.20.1 Xiromed Corporation Information
6.20.2 Xiromed Glycopyrrolate Injection Description and Business Overview
6.20.3 Xiromed Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Xiromed Glycopyrrolate Injection Product Portfolio
6.20.5 Xiromed Recent Developments/Updates
6.21 AuroMedics Pharma
6.21.1 AuroMedics Pharma Corporation Information
6.21.2 AuroMedics Pharma Glycopyrrolate Injection Description and Business Overview
6.21.3 AuroMedics Pharma Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.21.4 AuroMedics Pharma Glycopyrrolate Injection Product Portfolio
6.21.5 AuroMedics Pharma Recent Developments/Updates
6.22 Par Pharmaceutical
6.22.1 Par Pharmaceutical Corporation Information
6.22.2 Par Pharmaceutical Glycopyrrolate Injection Description and Business Overview
6.22.3 Par Pharmaceutical Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Par Pharmaceutical Glycopyrrolate Injection Product Portfolio
6.22.5 Par Pharmaceutical Recent Developments/Updates
6.23 Piramal Critical Care
6.23.1 Piramal Critical Care Corporation Information
6.23.2 Piramal Critical Care Glycopyrrolate Injection Description and Business Overview
6.23.3 Piramal Critical Care Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Piramal Critical Care Glycopyrrolate Injection Product Portfolio
6.23.5 Piramal Critical Care Recent Developments/Updates
6.24 Somerset Therapeutics
6.24.1 Somerset Therapeutics Corporation Information
6.24.2 Somerset Therapeutics Glycopyrrolate Injection Description and Business Overview
6.24.3 Somerset Therapeutics Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Somerset Therapeutics Glycopyrrolate Injection Product Portfolio
6.24.5 Somerset Therapeutics Recent Developments/Updates
6.25 West-ward Pharmaceutical
6.25.1 West-ward Pharmaceutical Corporation Information
6.25.2 West-ward Pharmaceutical Glycopyrrolate Injection Description and Business Overview
6.25.3 West-ward Pharmaceutical Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.25.4 West-ward Pharmaceutical Glycopyrrolate Injection Product Portfolio
6.25.5 West-ward Pharmaceutical Recent Developments/Updates
6.26 Zydus Pharmaceuticals
6.26.1 Zydus Pharmaceuticals Corporation Information
6.26.2 Zydus Pharmaceuticals Glycopyrrolate Injection Description and Business Overview
6.26.3 Zydus Pharmaceuticals Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.26.4 Zydus Pharmaceuticals Glycopyrrolate Injection Product Portfolio
6.26.5 Zydus Pharmaceuticals Recent Developments/Updates
6.27 Hengrui Pharmaceuticals
6.27.1 Hengrui Pharmaceuticals Corporation Information
6.27.2 Hengrui Pharmaceuticals Glycopyrrolate Injection Description and Business Overview
6.27.3 Hengrui Pharmaceuticals Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.27.4 Hengrui Pharmaceuticals Glycopyrrolate Injection Product Portfolio
6.27.5 Hengrui Pharmaceuticals Recent Developments/Updates
6.28 Jiabo Pharmaceutical
6.28.1 Jiabo Pharmaceutical Corporation Information
6.28.2 Jiabo Pharmaceutical Glycopyrrolate Injection Description and Business Overview
6.28.3 Jiabo Pharmaceutical Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.28.4 Jiabo Pharmaceutical Glycopyrrolate Injection Product Portfolio
6.28.5 Jiabo Pharmaceutical Recent Developments/Updates
6.29 Easton Biopharmaceuticals
6.29.1 Easton Biopharmaceuticals Corporation Information
6.29.2 Easton Biopharmaceuticals Glycopyrrolate Injection Description and Business Overview
6.29.3 Easton Biopharmaceuticals Glycopyrrolate Injection Sales, Revenue and Gross Margin (2018-2023)
6.29.4 Easton Biopharmaceuticals Glycopyrrolate Injection Product Portfolio
6.29.5 Easton Biopharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Glycopyrrolate Injection Industry Chain Analysis
7.2 Glycopyrrolate Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Glycopyrrolate Injection Production Mode & Process
7.4 Glycopyrrolate Injection Sales and Marketing
7.4.1 Glycopyrrolate Injection Sales Channels
7.4.2 Glycopyrrolate Injection Distributors
7.5 Glycopyrrolate Injection Customers
8 Glycopyrrolate Injection Market Dynamics
8.1 Glycopyrrolate Injection Industry Trends
8.2 Glycopyrrolate Injection Market Drivers
8.3 Glycopyrrolate Injection Market Challenges
8.4 Glycopyrrolate Injection Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ グリコピロレート注射液のグローバル市場2023年:0.2mg/ml、0.4mg/2ml、1mg/5ml、4mg/20ml(Global Glycopyrrolate Injection Market Research Report 2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆